<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001022</url>
  </required_header>
  <id_info>
    <org_study_id>ALG-020572-401</org_study_id>
    <nct_id>NCT05001022</nct_id>
  </id_info>
  <brief_title>A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects</brief_title>
  <official_title>A Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Subcutaneously Administered ALG-020572 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Doses in Healthy Volunteers (Part 1) and Multiple Doses in Subjects With Chronic Hepatitis B (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aligos Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aligos Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and&#xD;
      Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>up to 60 days for Part 1</time_frame>
    <description>The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>up to 120 days for Part 2</time_frame>
    <description>The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>Predose (0 hours) up to 45 Days (1080 hours)</time_frame>
    <description>Pharmacokinetic parameters of ALG-020572 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve [AUC]</measure>
    <time_frame>Predose (0 hours) up to 45 Days (1080 hours)</time_frame>
    <description>Pharmacokinetic parameters of ALG-020572 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration [Tmax]</measure>
    <time_frame>Predose (0 hours) up to 45 Days (1080 hours)</time_frame>
    <description>Pharmacokinetic parameters of ALG-020572 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-time [t1/2]</measure>
    <time_frame>Predose (0 hours) up to 45 Days (1080 hours)</time_frame>
    <description>Pharmacokinetic parameters of ALG-020572 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma Concentration [Cmin]</measure>
    <time_frame>Predose (0 hours) up to 45 Days (1080 hours)</time_frame>
    <description>Pharmacokinetic parameters of ALG-020572 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HBsAg (reduction) from baseline through Day 120 in Multiple Dose HBV Infected Patients</measure>
    <time_frame>Screening, Day 1, 2, 4, 8, 11, 15, 22, 29, 36, 45, 60, 90, 120</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>ALG-020572</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injections of ALG-020572 in HV or CHB subjects, up to 7 injections over the course of up to 29 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injections of placebo in HV or CHB subjects, up to 7 injections over the course of up to 29 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALG-020572</intervention_name>
    <description>Single or multiple doses of ALG-020572</description>
    <arm_group_label>ALG-020572</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single or multiple doses of Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Healthy Subjects:&#xD;
&#xD;
          1. Male and Female between 18 and 55 years old&#xD;
&#xD;
          2. Female subjects must have a negative serum pregnancy test at screening&#xD;
&#xD;
          3. BMI 18.0 to 32.0 kg/m^2&#xD;
&#xD;
          4. Subjects must have a 12-lead ECG that meets protocol criteria&#xD;
&#xD;
        Inclusion Criteria for CHB Subjects:&#xD;
&#xD;
          1. Male and Female between 18 and 75 years old&#xD;
&#xD;
          2. Female subjects must have a negative serum pregnancy test at screening&#xD;
&#xD;
          3. BMI 18.0 to 35.0 kg/m^2&#xD;
&#xD;
          4. For virally suppressed subjects, must be currently receiving HBV NA treatment for ≥6&#xD;
             months prior to screening. For currently not treated or treatment naïve subjects, must&#xD;
             have never received treatment OR have not been on treatment within 6 months prior to&#xD;
             randomization&#xD;
&#xD;
          5. Subjects must have a 12-lead ECG that meets protocol criteria&#xD;
&#xD;
        Exclusion Criteria for Healthy Subjects:&#xD;
&#xD;
          1. Subjects with any current or previous illness that, in the opinion of the&#xD;
             Investigator, might confound the results of the study or pose an additional risk in&#xD;
             administering study drug to the subject or that could prevent, limit, or confound the&#xD;
             protocol specified assessments or study results' interpretation&#xD;
&#xD;
          2. Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de&#xD;
             Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or history or&#xD;
             clinical evidence at screening of significant or unstable cardiac disease etc.&#xD;
&#xD;
          3. Subjects with a history of clinically significant drug allergy&#xD;
&#xD;
          4. Subject with current or history of clinically significant (as determined by the&#xD;
             Investigator) skin disease requiring intermittent or chronic treatment&#xD;
&#xD;
          5. Excessive use of alcohol defined as regular consumption of ≥14 units/week for women&#xD;
             and ≥21 units/week for men&#xD;
&#xD;
          6. Unwilling to abstain from alcohol use for 48 hours prior to start of dosing through&#xD;
             end of study follow up&#xD;
&#xD;
          7. Subjects with Hepatitis A, B, C, D, E or HIV-1/HIV-2 infection or acute infections&#xD;
             such as SARS- CoV-2 infection&#xD;
&#xD;
          8. Subjects with renal dysfunction (e.g., estimated creatinine clearance &lt;90 mL/min/1.73&#xD;
             m^2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration&#xD;
             [CKD-EPI] formula)&#xD;
&#xD;
        Exclusion Criteria for CHB Subjects:&#xD;
&#xD;
          1. Subjects with any current or previous illness that, in the opinion of the&#xD;
             Investigator, might confound the results of the study or pose an additional risk in&#xD;
             administering study drug to the subject or that could prevent, limit, or confound the&#xD;
             protocol specified assessments or study results' interpretation&#xD;
&#xD;
          2. Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de&#xD;
             Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or history or&#xD;
             clinical evidence at screening of significant or unstable cardiac disease etc.&#xD;
&#xD;
          3. Subjects with a history of clinically significant drug allergy&#xD;
&#xD;
          4. Subject with current or history of clinically significant (as determined by the&#xD;
             Investigator) skin disease requiring intermittent or chronic treatment&#xD;
&#xD;
          5. Excessive use of alcohol defined as regular consumption of ≥14 units/week for women&#xD;
             and ≥21 units/week for men&#xD;
&#xD;
          6. Subjects with Hepatitis A, C, D, E or HIV-1/HIV-2 infection or acute infections such&#xD;
             as SARS- CoV-2 infection&#xD;
&#xD;
          7. Subjects with renal dysfunction (e.g., estimated creatinine clearance &lt;90 mL/min/1.73&#xD;
             m^2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration&#xD;
             [CKD-EPI] formula)&#xD;
&#xD;
          8. Subject with any history or current evidence of hepatic decompensation such as:&#xD;
             variceal bleeding, spontaneous bacterial peritonitis, ascites, hepatic encephalopathy,&#xD;
             or active jaundice (within the last year)&#xD;
&#xD;
          9. Subjects must have absence of signs of hepatocellular carcinoma&#xD;
&#xD;
         10. Subjects with history or current liver cirrhosis&#xD;
&#xD;
         11. Subjects positive for anti-HBs antibodies&#xD;
&#xD;
         12. Subjects with liver fibrosis that is classified as Metavir Score ≥F3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Zhao</last_name>
      <phone>6493733474</phone>
      <phone_ext>7020</phone_ext>
      <email>orbit@nzcr.co.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

